Rationale, design and baseline patient characteristics of the optimal type 2 diabetes management including benchmarking and standard treatment study in Greece

Abstract

Despite relevant treatment, there is a poor control of diabetes, hypertension and hyperlipidemia in Greek outpatients with type 2 diabetes.

Adherence to the National Guidelines for Follow-Up Protocol in Subjects with Type 2 Diabetes Mellitus in Greece: The GLANCE Study

“…In the GLANCE study, the LDL-C target was achieved by 57% of subjects, compared to 31% [15] and 60% [36] in previous Greek studies. In addition, adequate SBP control was achieved in the GLANCE study by 55% of subjects compared to a previously reported rate of 27% [15], while the composite metabolic control rate was 22% in this work compared to about 5% in a previous study [15]. Arguably, our results point to some improvement-or at least some degree of stability-in the observed rates compared to those reported previously.…”

“…Other studies have reported glycaemic control rates of 53-67% [15,30,37]. In the GLANCE study, the LDL-C target was achieved by 57% of subjects, compared to 31% [15] and 60% [36] in previous Greek studies. In addition, adequate SBP control was achieved in the GLANCE study by 55% of subjects compared to a previously reported rate of 27% [15], while the composite metabolic control rate was 22% in this work compared to about 5% in a previous study [15].…”

“…In the recent AGREEMENT registry of 1191 adult patients with T2DM, adequate glycaemic control was achieved by 53% of subjects overall and by 65% of non-insulin-treated subjects [36]. Other studies have reported glycaemic control rates of 53-67% [15,30,37]. In the GLANCE study, the LDL-C target was achieved by 57% of subjects, compared to 31% [15] and 60% [36] in previous Greek studies.…”

“…Current management goals include achieving adequate glycaemic control and addressing vascular risk factors, notably blood pressure (BP), lipids, among others [ 7 – 10 ]. In general, the achievement of therapeutic targets in T2DM is not optimal [ 11 , 12 ]; this also holds true for Greece [ 13 – 16 ], where the achievement rates of glycated haemoglobin (HbA 1c ) and BP targets have been reported to be 53 and 27%, respectively [ 15 ]. Achievement of therapeutic targets may be linked to adherence to diabetes standards of medical care recommendations [ 17 – 19 ].…”

Real-World Adequacy of Glycaemic Control in Treatment-Naïve Greek Patients with Type 2 Diabetes Mellitus Initiating Treatment with Metformin Monotherapy at the Maximum Tolerated Dose: The Reload Study

“…In Greece, more than 2 thirds of patients with T2DM receiving anti-hyperglycaemic monotherapy are treated with metformin [16], which is in alignment with the HDA treatment guidelines [4]. However, 32.9 % to 47.0 % of actively treated patients have HbA 1c levels ≥ 7 % ( ≥ 53 mmol/mol) for significant periods of time [17,18]. In the Europe-wide PANORAMA study, which included Greece, one of the barriers to glycaemic control attainment is clinical inertia [19].…”